Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 572171, 9 pages
http://dx.doi.org/10.1155/2015/572171
Research Article

TLR3 Plays Significant Roles against HBV-Associated HCC

1Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, China
2Department of Pathological Anatomy, Nantong University, Nantong, Jiangsu 226001, China

Received 28 July 2014; Revised 13 November 2014; Accepted 13 November 2014

Academic Editor: Zhongxia Wang

Copyright © 2015 Xiao-lan Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y.-J. Jin, Y.-H. Chung, J. A. Kim et al., “Factors predisposing metastatic tumor antigen 1 overexpression in hepatitis B virus associated hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 57, no. 11, pp. 2917–2923, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. Z. Li, W. Yuan, S. Ning, J. Li, W. Zhai, and S. Zhang, “Role of leptin receptor (LEPR) gene polymorphisms and haplotypes in susceptibility to hepatocellular carcinoma in subjects with chronic hepatitis b virus infection,” Molecular Diagnosis and Therapy, vol. 16, no. 6, pp. 383–388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. M. Hassan, L.-Y. Hwang, C. J. Hatten et al., “Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus,” Hepatology, vol. 36, no. 5, pp. 1206–1213, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. C.-A. Sun, D.-M. Wu, C.-C. Lin et al., “Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan,” American Journal of Epidemiology, vol. 157, no. 8, pp. 674–682, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Kimura, K. Kakimi, S. Wieland, L. G. Guidotti, and F. V. Chisari, “Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice,” Journal of Immunology, vol. 169, no. 9, pp. 5188–5195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Kimura, K. Kakimi, S. Wieland, L. G. Guiotti, and F. V. Chisari, “Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic micet,” Journal of Virology, vol. 76, no. 21, pp. 10702–10707, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Alexopoulou, A. C. Holt, R. Medzhitov, and R. A. Flavell, “Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3,” Nature, vol. 413, no. 6857, pp. 732–738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Karikó, P. Bhuyan, J. Capodici et al., “Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3,” Cells Tissues Organs, vol. 177, no. 3, pp. 132–138, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. W. J. Kaiser and M. K. Offermann, “Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif,” Journal of Immunology, vol. 174, no. 8, pp. 4942–4952, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-J. Han, X. Su, L.-G. Xu, L.-H. Bin, J. Zhang, and H.-B. Shu, “Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways,” The Journal of Biological Chemistry, vol. 279, no. 15, pp. 15652–15661, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Karimi-Googheri and M. K. Arababadi, “TLR3 plays significant roles against hepatitis B virus,” Molecular Biology Reports, vol. 41, no. 5, pp. 3279–3286, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Broering, M. Lutterbeck, M. Trippler et al., “Long-term stimulation of toll-like receptor 3 in primary human hepatocytes leads to sensitization for antiviral responses induced by poly I: C treatment,” Journal of Viral Hepatitis, vol. 21, pp. 480–490, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Y. Xu, L. Chen, G. L. Wang et al., “A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo,” BMC Cancer, vol. 13, article 527, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Schröder and A. G. Bowie, “TLR3 in antiviral immunity: key player or bystander?” Trends in Immunology, vol. 26, no. 9, pp. 462–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Karimi-Googheri and M. K. Arababadi, “TLR3 plays significant roles against hepatitis B virus,” Molecular Biology Reports, vol. 41, no. 5, pp. 3279–3289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-Y. Chen, L.-Y. Wang, R. M. Lunn et al., “Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls,” International Journal of Cancer, vol. 99, no. 1, pp. 14–21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. H.-C. Wu, Q. Wang, L.-W. Wang et al., “Polycyclic aromatic hydrocarbon- and aflatoxin-albumin adducts, hepatitis B virus infection and hepatocellular carcinoma in Taiwan,” Cancer Letters, vol. 252, no. 1, pp. 104–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. G. A. Farina, M. R. York, M. Di Marzio et al., “Poly(I:C) drives type i IFN- and TGFΒ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis,” Journal of Investigative Dermatology, vol. 130, no. 11, pp. 2583–2593, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Guillot, R. Le Goffic, S. Bloch et al., “Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus,” The Journal of Biological Chemistry, vol. 280, no. 7, pp. 5571–5580, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Li, Z. Chen, N. Kato, M. Gale Jr., and S. M. Lemon, “Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-β production in hepatocytes,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 16739–16747, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Matsumoto, K. Funami, H. Oshiumi, and T. Seya, “Toll-like receptor 3: a link between toll-like receptor, interferon and viruses,” Microbiology and Immunology, vol. 48, no. 3, pp. 147–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. M. L. Hanke and T. Kielian, “Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential,” Clinical Science, vol. 121, no. 9, pp. 367–387, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Chew, C. Tow, C. Huang et al., “Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients,” Journal of the National Cancer Institute, vol. 104, no. 23, pp. 1796–1807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Yoneda, K. Sugimoto, K. Shiraki et al., “Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: Differential signaling mechanisms of TLR3-induced NF-κB activation and apoptosis,” International Journal of Oncology, vol. 33, no. 5, pp. 929–936, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Bsibsi, C. Persoon-Deen, R. W. H. Verwer, S. Meeuwsen, R. Ravid, and J. M. Van Noort, “Toll-like receptor 3 on adult human astrocytes triggers production of neuroprotective mediators,” GLIA, vol. 53, no. 7, pp. 688–695, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Mcclary, R. Koch, F. V. Chisari, and L. G. Guidotti, “Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines,” Journal of Virology, vol. 74, no. 5, pp. 2255–2264, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Wang, M. Trippler, R. Pei et al., “Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication,” Journal of Hepatology, vol. 51, no. 6, pp. 1037–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari, “Toll-like receptor signaling inhibits hepatitis B virus replication in vivo,” Journal of Virology, vol. 79, no. 11, pp. 7269–7272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Wu, M. Lu, Z. Meng et al., “Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice,” Hepatology, vol. 46, no. 6, pp. 1769–1778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Kanda, R. Steele, R. Ray, and R. B. Ray, “Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes,” Journal of Virology, vol. 81, no. 22, pp. 12375–12381, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. J. C. Ferreon, A. C. M. Ferreon, K. Li, and S. M. Lemon, “Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease,” The Journal of Biological Chemistry, vol. 280, no. 21, pp. 20483–20492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Zorde-Khvalevsky, R. Abramovitch, H. Barash et al., “Toll-like receptor 3 signaling attenuates liver regeneration,” Hepatology, vol. 50, no. 1, pp. 198–206, 2009. View at Publisher · View at Google Scholar · View at Scopus